| <P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 31.5pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">英国药品和健康产品管理局（</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">MHRA</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">）在</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">8</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">月的《药品安全更新》杂志中发表了关于沙奎那韦有明显的延长</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">和</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期的作用信息。并建议心律不齐的高危患者和正在使用其他可能导致</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">和</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">或</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期延长的药物的患者，禁用沙奎那韦。如果患者出现心律不齐、</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">延长或</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">延长，应当停用沙奎那韦。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 31.5pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">沙奎那韦（商品名</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">Invirase</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">）是蛋白酶抑制剂，适用于和利托那韦及其他抗逆转录病毒药物联合，治疗</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">HIV</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">感染。成年人和</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">16</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">岁以上的青少年用沙奎那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦的标准剂量是</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">1000mg/100mg</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">，每天</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">2</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">次。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 31.5pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">2005</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">年</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">2</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">月，一项研究提示，包括沙奎那韦在内的一些蛋白酶抑制剂，容易使患者的</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期延长，出现尖端扭转型室性心动过速。因此，就沙奎那韦对心脏传导的影响做了进一步研究。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 31.5pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">一项全面的</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">研究评价了与安慰剂及活性对照药莫西沙星相比，治疗剂量（</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">1000 mg/100 mg</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">每天</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">2</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">次）和超治疗剂量（</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">1500 mg/100 mg</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">每天</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">2</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">次）的沙奎那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦对</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期的影响。该研究结果表明，沙奎那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦组的</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期延长，其风险大于莫西沙星。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">没有受试者的</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">延长超过</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">500</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">毫秒，或出现尖端扭转型室性心动过速。晕厥和晕厥前期病例发生于用药速度过快时，沙奎那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦用药次数多时比较多见。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 31.5pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">根据这些结果，目前心律不齐的高危患者和正在使用其他可能导致</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">和</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">或</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期延长的药物的患者，禁用沙奎那韦。也不宜使用其他可使沙奎那韦血浆浓度升高的药物，如细胞色素</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">p450 3A4</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">酶的强抑制剂（如蛋白酶抑制剂奈非那韦、抗真菌药伊曲康唑，以及质子泵抑制剂，如奥美拉唑）。有心律失常中度风险的患者使用沙奎那韦的警告信息，以及关于进行心电图监测的建议也已经添加到产品说明书中。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">下表给出了因为可能发生致命性心律失常，禁止与沙奎那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦合用的药物：</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P></P>
<TABLE style="WIDTH: 100%; BORDER-COLLAPSE: collapse" border=0 cellSpacing=0 cellPadding=0 width="100%">
<TBODY>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28.1pt; LAYOUT-GRID-MODE: char" align=left><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">药物类别</SPAN></B><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></B></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">禁止与利托那韦</SPAN></B><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN></B><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">沙奎那韦合用的药物</SPAN></B><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></B></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">蛋白酶抑制剂</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">阿扎那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦、洛匹那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">利托那韦</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">麻醉性镇痛药</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">美沙酮</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">抗心律失常药</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">二氢奎尼丁、胺碘酮、氟卡尼、多非利特、索他洛尔</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">三环类抗抑郁药</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">阿米替林、丙咪嗪、曲唑酮</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">抗感染药</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">克拉霉素、红霉素</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">抗精神病药物</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">氯氮平、匹莫齐特、氟哌啶醇、舍吲哚、吩塞秦类</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">抗组胺药</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">特非那定、阿司咪唑和咪唑斯汀</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR>
<TR>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: windowtext 1pt solid; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 39.02%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="39%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">5</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">型磷酸二酯酶抑制剂</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD>
<TD style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0cm; PADDING-LEFT: 5.4pt; WIDTH: 60.98%; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1pt solid; PADDING-TOP: 0cm" vAlign=top width="60%">
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">西地那非、伐地那非、他达拉非</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P></TD></TR></TBODY></TABLE>
<P></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28.1pt; LAYOUT-GRID-MODE: char" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN> </P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28.1pt; LAYOUT-GRID-MODE: char" align=left><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">给医疗专业人员的建议：</SPAN></B><B><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></B></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char; MARGIN-LEFT: 25.2pt; tab-stops: list 21.0pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: Wingdings; FONT-SIZE: 11.5pt">?</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-SIZE: 7pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">先天性或后天获得性</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">延长的患者，或者有其他基础疾病容易发生心律失常的患者，包括合用能使</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">和</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">/</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">或</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期延长的其他药物的患者，不要使用沙奎那韦。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char; MARGIN-LEFT: 25.2pt; tab-stops: list 21.0pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: Wingdings; FONT-SIZE: 11.5pt">?</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-SIZE: 7pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">用沙奎那韦治疗时，要避免使用能使沙奎那韦血浆浓度升高的药物，除非别无选择。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char; MARGIN-LEFT: 25.2pt; tab-stops: list 21.0pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: Wingdings; FONT-SIZE: 11.5pt">?</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-SIZE: 7pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">沙奎那韦的用药剂量不要超过推荐剂量，因为沙奎那韦的血浆浓度升高，</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">和</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">间期延长的幅度可能会加大。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char; MARGIN-LEFT: 25.2pt; tab-stops: list 21.0pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: Wingdings; FONT-SIZE: 11.5pt">?</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-SIZE: 7pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">基线时可考虑做心电图，随后复查（如患者合用其他药物可能使沙奎那韦血浆浓度升高时）。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char; MARGIN-LEFT: 25.2pt; tab-stops: list 21.0pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: Wingdings; FONT-SIZE: 11.5pt">?</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-SIZE: 7pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">如果患者出现心律失常、</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">QT</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">延长或</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt">PR</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">延长，要停用沙奎那韦。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P>
<P style="TEXT-ALIGN: left; LINE-HEIGHT: 150%; TEXT-INDENT: 28pt; LAYOUT-GRID-MODE: char; MARGIN-LEFT: 25.2pt; tab-stops: list 21.0pt" align=left><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: Wingdings; FONT-SIZE: 11.5pt">?</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-SIZE: 7pt"> </SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: 宋体; FONT-SIZE: 11.5pt">警告患者沙奎那韦有引起心律失常的危险，若有心律失常的任何迹象（如，心悸、晕厥、晕厥前期），要及时向医生报告。</SPAN><SPAN style="LINE-HEIGHT: 150%; FONT-FAMILY: ??; FONT-SIZE: 11.5pt"></SPAN></P> |
